Here are the Form 4 insider transactions from Adverum Biotechnologies, Inc. (ADVM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADVM filings page.
Adverum Biotechnologies, Inc. reported a major ownership change linked to its sale to Eli Lilly. A large Frazier Life Sciences affiliated holder reported the disposition of 4,288,949 shares of Adverum common stock on December 9, 2025, at $3.56 per share, leaving 0 shares beneficially owned after the transaction.
The Form 4 explains that this took place upon consummation of a merger under an Agreement and Plan of Merger dated October 24, 2025 among Adverum, Eli Lilly and Company and its wholly owned subsidiary Tigers Acquisition Corporation, including a related tender offer. Under the offer, each Adverum share held by the reporting person was purchased for $3.56 in cash plus one non‑tradable contingent value right (CVR) that may pay up to an additional $8.91 per CVR in cash if two milestones described in the merger agreement are achieved.